

Are You or Your Child Facing Challenges Due to CAH?

Consider Joining a Clinical Research Study



Crinetics is a pharmaceutical company that develops much-needed therapies for people with endocrine diseases. We are currently enrolling adults and children who have been diagnosed with classic congenital adrenal hyperplasia (CAH).

The Calm-CAH (adult) and Balance-CAH (pediatric) studies are looking to understand the safety and effectiveness of an investigational study drug, atumelnant, whether it may reduce the dosage needed for steroid medications like glucocorticoids (GCs), and how it may help manage symptoms of CAH.

To participate in these studies, you or your child must:

- Be 1 to 74 years of age
- Have received a diagnosis of classic CAH
- Be on a stable GC regimen (for example: modified-release hydrocortisone, cortisone acetate, prednisolone, prednisone, methylprednisolone, and dexamethasone)

Additional requirements apply, which the study team will discuss with you.

Atumelnant is an investigational study drug, which means it has not been approved by any regulatory authority and is still under investigation as a potential treatment for CAH.



To learn more or to see if you or your child may qualify, scan the QR code or visit **CrineticsCAH.com**.